Purpose: We studied overall survival and prognostic factors in patients with sarcomatoid renal cell carcinoma treated with nephrectomy and systemic therapy in the cytokine and targeted therapy eras. Materials and Methods: This is a retrospective study of patients with sarcomatoid renal cell carcinoma who underwent nephrectomy and received systemic therapy at our center in the cytokine era (1987 to 2005) or the targeted therapy era (2006 to 2015). Multivariate regression models were used to determine the association of covariables with survival. Results: Of the 199 patients with sarcomatoid renal cell carcinoma 167 (83.9%) died (median overall survival 16.5 months, 95% CI 15.2e20.9). Survival of patients with clear cell histology was significantly longer vs those with nonclear cell histology (p ¼ 0.034). Patients with synchronous metastatic disease had significantly shorter survival than patients with metachronous metastatic disease (median 12.1 vs 23.3 months, p ¼ 0.0064). Biopsy of the primary tumor or a metastatic site could detect the presence of sarcomatoid features in only 7.5% of cases. Although a significant improvement in survival rate was observed in the first year in patients treated in the targeted therapy era (p ¼ 0.011), this effect was attenuated at year 2, disappeared at years 3 to 5 after diagnosis and was not evident in patients with poor risk features.
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Supported by the National Institutes of Health Grant T32 CA009666 (PM) and M. Due to the rarity of sRCC there is a paucity of data on the optimal treatment of patients with advanced disease. Cytotoxic chemotherapy and/or cytokines historically produced minimal responses and survival benefits. 3,4,7e10 Targeted therapies directed against the VEGF and mTOR pathways have revolutionized the management of advanced clear cell RCC. However, only small series exist that investigated the particular entity of sarcomatoid RCC. 6,11e21 We present a retrospective analysis of our institutional sRCC database and describe the clinical and pathological characteristics of advanced sRCC.
The study objective was to analyze the outcome of patients with metastatic sRCC in different therapeutic eras (before 2006 vs 2006 and later) and explore factors associated with patient survival.
PATIENTS AND METHODS
Patients with sRCC who had nephrectomy and received systemic therapy for metastatic disease at University of Texas M. D. Anderson Cancer Center from 1987 to 2015 were retrospectively identified from a secure database. The study was approved by our institutional review board, and it was performed in accordance with the Declaration of Helsinki and good clinical practice guidelines. Patients had to have sarcomatoid features in the nephrectomy pathology specimen to be included in analysis regardless of the underlying histological RCC subtype.
Demographics, clinical features, performance status, symptoms at diagnosis, laboratory values, operative notes, pathological features, postoperative evaluation, systemic therapies and followup were recorded and used for CCI calculation. CCI was not age adjusted and no points were given for localized or metastatic sRCC. Points were added to CCI if patients had localized or metastatic malignancies other than sRCC. Risk stratification was performed using IMDC and MSKCC prognostic models. 22, 23 Systemic therapies were grouped as targeted (sunitinib, sorafenib, bevacizumab, axitinib, pazopanib, erlotinib, temsirolimus or everolimus), immunotherapy (interleukin-2, interferon-a, dendritic cells pulsed with tumor lysate vaccination, heat shock protein peptide complex-96 vaccination, nivolumab or ipilimumab), chemotherapy (cyclophosphamide, doxorubicin, 5-fluorouracil, gemcitabine, cisplatin or capecitabine) or combinations. The combination group consisted of 2 subgroups, including 1 of targeted therapies and another of therapies other than targeted therapies.
Unless otherwise specified OS was measured from time of diagnosis until death of any cause or the last followup. Patients who were alive at the time of the last contact were censored on that date. OS curves were estimated by the Kaplan-Meier method and compared using the log rank test. Median followup was calculated using the reverse Kaplan-Meier method. Cox regression models were used to determine the association of variables with OS with p <0.05 considered statistically significant.
Multivariate analysis was done using backward variable selection. Cutoff points of numerical variables were selected based on univariate analysis of terciles. Plots of median OS and OS probabilities at select times as smooth functions of year of diagnosis were generated using nonparametric quantile regression adapted for right censored data.
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RESULTS
Clinical and Pathological Characteristics
We identified 199 patients with sRCC who underwent nephrectomy and received systemic therapy. Median age of all patients at initial diagnosis was 57 years with a 2:1 male preponderance (table 1). Of the patients 92% were symptomatic at initial diagnosis with pain as the most common symptom in 52.3% followed by hematuria in 34.7%. Of the patients 79.9% were white. Median time to the initiation of systemic therapy from nephrectomy was 3.7 months (range 0 to 88). Median followup was 8.8 years from diagnosis and 8.6 years from nephrectomy.
Preoperative biopsy was performed in 133 patients, including biopsy of the primary tumor in 76 and biopsy of a metastatic site in 57. However, the diagnosis of sRCC was made in only 10 cases, including 3 kidney biopsies and 7 biopsies of a metastatic site, based on this biopsy. Of the 199 patients 139 (69.9%) had metastatic disease at initial presentation and in 60 (30.1%) metastatic disease developed after nephrectomy was performed with curative intent. All 199 patients had confirmed sarcomatoid features in the nephrectomy specimens. Two preoperative laboratory values were significantly associated with OS on multivariable analysis, including preoperative corrected serum calcium greater than 9.2 mg/dl (HR 2.17, 95% CI 1.4e3.35, p ¼ 0.0005) and preoperative white blood count greater than 9.3 K/ml (HR 1.64, 95% CI 1.05e2.58, p ¼ 0.030). The neutrophil-to-lymphocyte ratio prior to nephrectomy was evaluable in 153 patients. Only 4 patients (2.6%) had a neutrophil-to-lymphocyte ratio less than 3.0. However, when this ratio was dichotomized at the median of 3.23, it was significantly associated with OS (HR 2.0, 95% CI 1.1e3.3, p ¼ 0.021).
Tumor stage at presentation (localized vs regional/distant metastases) and histology of the epithelial component (clear cell vs nonclear cell) were also independently associated with OS on multivariable analysis (HR 1.94, 95% CI 1.16e3.22, 
DISCUSSION
Of our patients 69.9% presented with metastatic disease at initial diagnosis while in the rest metastasis developed after nephrectomy. This is consistent with prior literature suggesting that patients with sRCC are more likely to be diagnosed at a higher clinical stage than those with clear cell RCC without sarcomatoid dedifferentation. 25 In addition, 92% of our patients presented with symptoms related to the primary tumor or metastatic disease. Consistent with previous reports 26 our analysis suggests that patients with a higher percent of sarcomatoid component have shorter median OS (supplementary fig. 4 , http://jurology.com/).
Detecting sarcomatoid features by biopsy of the primary renal tumor or a metastatic site prior to nephrectomy is challenging. Currently there are no biochemical or immunological markers specific to sRCC and the sensitivity of preoperative biopsies for sRCC is low, although it may be improved by multiquadrant biopsies. 27 Indeed, in our large cohort only 7.5% of patients with sRCC were identified by biopsy before nephrectomy. Some groups have accordingly suggested using preoperative imaging modalities such as magnetic resonance imaging to identify sRCC, although these approaches do not yet have significantly improved diagnostic accuracy.
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Notably in our analysis we did not include patients diagnosed with biopsy proven sRCC who did not undergo nephrectomy.
Although various cytotoxic chemotherapies have been studied for metastatic sRCC, none has shown a clear benefit. An earlier series published in 1987 from our institution did not show a significant advantage of any particular chemotherapy, although doxorubicin based chemotherapy produced a complete response in 2 of 8 patients. 3 In 2011 ECOG (Eastern Cooperative Oncology Group) reported the results of a phase II trial of doxorubicin and gemcitabine in 39 patients with metastatic sRCC, which showed a 16% response rate and significant toxicity associated with the regimen. 29 In the current study 7% of patients received cytotoxic chemotherapy with no observed meaningful survival benefit compared with other therapeutic modalities (supplementary fig. 1 , http://jurology.com/).
There are few studies focusing on treatment modalities for sRCC in the targeted therapy era (supplementary table, http://jurology.com/). Currently we report what is to our knowledge the largest single institution experience of treatment and outcomes in patients with metastatic sRCC who underwent nephrectomy as part of treatment and received systemic therapy.
One of the goals of our study was to determine whether the introduction of targeted therapies has led to improved survival outcomes in these patients. Since VEGF directed therapies and mTOR inhibitors entered the clinic in 2005, there has been a dramatic improvement in RCC outcomes in general, mainly in patients harboring the clear cell RCC subtype. Published studies investigating targeted therapies alone or in combination with cytotoxic chemotherapy for sRCC have shown modest or no improvement in survival outcomes. 16,18e20 In this study we found a 1-year OS benefit in patients diagnosed after 2005 compared with those diagnosed before 2005. However, this improvement in OS was not durable as the 3 and 5-year overall survival rates were similar in patients diagnosed in the cytokine era and those diagnosed in the targeted therapy era. Of note is that we were unable to detect a statistically significant difference in OS among patients treated with first line targeted therapies compared with other treatments. Therefore, it is clear that novel and more effective therapies are needed to achieve better clinical outcomes and prolong survival in patients with sRCC. Outcomes in patients with sRCC may differ among studies as we only included those with sRCC who underwent nephrectomy. Currently it is unclear how much nephrectomy affects the survival outcome of patients with sRCC.
Potential confounders such as earlier diagnosis and improved supportive care may also account for the improved outcomes with time. They may explain why the improvement in survival began in 2000 before targeted therapies became common practice rather than in 2005 (fig. 4) . Indeed, table 2 suggests a trend toward lower rates of stage IV disease in patients diagnosed in the targeted therapy era, although this did not reach statistical significance. In addition, patients with a poor risk classification by MSKCC or IMDC criteria have not experienced any improvement in survival outcomes in more than 2 decades (supplementary fig. 3 , http://jurology.com/). These patients carry the worst prognosis and are in dire need of novel treatment strategies.
Our study differs from prior data in terms of longer followup and in being the largest single institution cohort to date. In addition, we were able to study systemic therapies used for a long period, which allowed us to compare therapies in different eras.
The limitations of our study include its retrospective nature and the heterogeneous systemic therapies that patients received during the years. However, we controlled for several clinical and pathological variables known to influence survival outcomes, including CCI, which is a validated risk adjustment tool that accounts for the effect of comorbidities on mortality. 30 We were unable to specifically control for the survival effect of targeted therapies when they were given beyond the first line setting.
Despite these limitations we confirmed that survival in patients with sRCC without poor risk features who underwent nephrectomy has improved with time in a large single center analysis of sRCC spanning 3 decades of experience.
CONCLUSIONS
We found that the survival of patients with advanced sRCC who undergo nephrectomy has been steadily improving since 2000. The reasons for this may be the introduction of targeted therapies, earlier diagnosis and improved supportive care. However, this survival benefit does not extend beyond the first 2 years after diagnosis and it is not seen in patients with poor risk features. Therefore, there is an unmet need to develop more effective 
EDITORIAL COMMENTS
Keskin et al report a large, single center, retrospective experience in patients with sRCC who underwent nephrectomy and systemic treatment.
As expected a large part of the patients presented with advanced disease and a negative prognostic classification. A transient advantage in overall survival was shown in patients treated with tyrosine kinase or mTOR inhibitors but no difference was observed in the long-term outcome.
To date the presence of sarcomatoid histology in metastatic RCC has been associated with a poor outcome. This is also because of limited data for decision making with no place for chemotherapy and sparse data on targeted agents (references 7 and 20 in article). However, as we enter the new immunotherapy era something may change. Recent data suggest a possible relationship between sarcomatoid features and the probability of a response to the new immune checkpoint inhibitors. 1, 2 Has the wind changed for sRCC?
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